Merck, Keytruda and WSJ
Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...
In a grim update, Merck announced it is temporarily halting shipments of HPV vaccine Gardasil—its second-biggest product—to China. “Like many other companies, we’ve seen increased pressure ...
Looking at options history for Merck & Co MRK we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish ...
It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback